Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ibio Inc (IBIO)

Ibio Inc (IBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 252,706
  • Shares Outstanding, K 217,850
  • Annual Sales, $ 1,640 K
  • Annual Income, $ -16,440 K
  • 60-Month Beta -6.24
  • Price/Sales 65.31
  • Price/Cash Flow N/A
  • Price/Book 2.51
Trade IBIO with:

Options Overview

Details
  • Implied Volatility 149.56%
  • Historical Volatility 50.82%
  • IV Percentile 46%
  • IV Rank 44.78%
  • IV High 222.55% on 02/01/21
  • IV Low 90.37% on 07/23/21
  • Put/Call Vol Ratio 0.13
  • Today's Volume 3,585
  • Volume Avg (30-Day) 1,472
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 54,494
  • Open Int (30-Day) 52,555

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0800 +13.89%
on 09/16/21
1.3350 -7.87%
on 08/30/21
+0.0800 (+6.96%)
since 08/17/21
3-Month
1.0800 +13.89%
on 09/16/21
1.6300 -24.54%
on 06/28/21
-0.3100 (-20.13%)
since 06/17/21
52-Week
1.0300 +19.42%
on 12/31/20
2.8300 -56.54%
on 02/10/21
-1.1200 (-47.66%)
since 09/17/20

Most Recent Stories

More News
iBio Appoints William D. Clark to its Board of Directors

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, announced today the appointment of...

IBIO : 1.2300 (+6.03%)
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics

- iBio licenses a novel antibody targeting regulatory T cells -

IBIO : 1.2300 (+6.03%)
The Surge in New Cases Reinforces the Importance of a Healthy Lifestyle

/PRNewswire/ -- While most of the economy has reopened, the number of new cases is once again on the rise. This time, two variants of COVID-19, the delta and lambda variants, are causing the numbers of...

TOMDF : 0.0420 (+3.70%)
AGEN : 5.83 (+4.67%)
HOLX : 77.63 (+0.62%)
VBIV : 3.31 (+3.12%)
IBIO : 1.2300 (+6.03%)
Are Covid Stocks Back In Play? 3 To Watch If You Think They Are

The New Delta Variant Has Brought Coronavirus Into The Forefront Again. Is This Vaccine Stock 2.0?

NVAX : 237.54 (+0.11%)
IBB : 173.61 (+0.64%)
IBIO : 1.2300 (+6.03%)
APT : 7.90 (+3.54%)
SPY : 441.40 (-1.29%)
QQQ : 373.83 (-1.18%)
OCGN : 7.93 (+5.17%)
PFE : 43.89 (-1.30%)
MRNA : 430.05 (-2.41%)
AEMD : 3.45 (-1.43%)
BNTX : 359.18 (-3.61%)
GILD : 71.61 (+0.39%)
Thinking about buying stock in Ion Geophysical, Moneygram International, Akebia Therapeutics, iBio, or Exela Technologies?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA.

IBIO : 1.2300 (+6.03%)
XELA : 2.05 (-2.38%)
AKBA : 2.90 (+2.84%)
MGI : 9.05 (+1.69%)
IO : 1.4600 (-7.59%)
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate...

IBIO : 1.2300 (+6.03%)
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its...

IBIO : 1.2300 (+6.03%)
Thinking about buying stock in Vaxart, Graybug Vision, Jaguar Health, iBio, or Aptinyx?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VXRT, GRAY, JAGX, IBIO, and APTX.

IBIO : 1.2300 (+6.03%)
APTX : 2.48 (+1.22%)
GRAY : 3.50 (-4.63%)
VXRT : 8.41 (+2.31%)
JAGX : 2.41 (+1.69%)
iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, announced today the appointment of Evert (Eef) Schimmelpennink to its Board of...

PFNX : 12.75 (-0.08%)
IBIO : 1.2300 (+6.03%)
Global C1 Inhibitors Market Share at 18.6% CAGR Expected to Generate Revenue of USD 9,800 Million by 2026: Facts & Factors

Facts and Factors have published a new research report titled "C1 Inhibitors Market By Source (Human Derived & Recombinant Derived C1 Inhibitors), By Mode of Administration (Intravenous & Subcutaneous),...

IBIO : 1.2300 (+6.03%)
IONS : 37.21 (+2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture...

See More

Key Turning Points

3rd Resistance Point 1.4067
2nd Resistance Point 1.3233
1st Resistance Point 1.2767
Last Price 1.2300
1st Support Level 1.1467
2nd Support Level 1.0633
3rd Support Level 1.0167

See More

52-Week High 2.8300
Fibonacci 61.8% 2.1424
Fibonacci 50% 1.9300
Fibonacci 38.2% 1.7176
Last Price 1.2300
52-Week Low 1.0300

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar